CYTIVA/PALL CORPORATE SESSION Accelerating the path to new cell and gene therapies
Thursday, June 1, 2023 06:00 PM - 07:30 PM
Salle Maillot
Corporate Session
Accelerating the path to new cell and gene therapies
Chairs
Emmanuelle Cameau, Strategic Technology Partnership Leader, Cell & Gene Therapy, Cytiva | Pall
Sabrina Carmichael, CGT Fast Track Global Training Leader, at Cytiva | Pall
Speakers
Emmanuel Abate, President, Genomic Medicine at Cytiva | Pall
Manuela Cota, Upstream Vector Development Supervisor at AGC Biologics Italy
Rob Tressler, Chief Scientific Officer at Excellos
Lauren Bor, Process Development Manager, TC Biopharm
Hugh Salter, PhD, Chief Scientific Officer at Anocca AB
Stephan Fricke, Head of Department Cell and Gene Therapy Development at Fraunhofer IZI
Reto Ritschard, Head of Production (Manufacturing Manager) Cancer Immunotherapy, University Hospital Basel, Switzerland
As genomic medicines continue to move toward commercialization, a reliable, scalable, and flexible manufacturing process is crucial to ensure these novel therapies reach patients.
This symposium showcases how the combination of Pall Life Sciences and Cytiva helps bring advanced therapies to patients faster and more efficiently by supplying complete solutions to support any process.
This session includes a customer case study (AGC Biologics Italy) on an efficient and scalable production process for lentiviral vectors, which can be further used for CAR-T manufacturing.
The second part is a roundtable with industry leaders from Anocca AB, TC BioPharm, Excellos, Fraunhofer IZI and University Hospital Basel on overcoming challenges and opportunities to advance new cell therapies.
Chairs
Emmanuelle Cameau, Strategic Technology Partnership Leader, Cell & Gene Therapy, Cytiva | Pall
Sabrina Carmichael, CGT Fast Track Global Training Leader, at Cytiva | Pall
Speakers
Emmanuel Abate, President, Genomic Medicine at Cytiva | Pall
Manuela Cota, Upstream Vector Development Supervisor at AGC Biologics Italy
Rob Tressler, Chief Scientific Officer at Excellos
Lauren Bor, Process Development Manager, TC Biopharm
Hugh Salter, PhD, Chief Scientific Officer at Anocca AB
Stephan Fricke, Head of Department Cell and Gene Therapy Development at Fraunhofer IZI
Reto Ritschard, Head of Production (Manufacturing Manager) Cancer Immunotherapy, University Hospital Basel, Switzerland
As genomic medicines continue to move toward commercialization, a reliable, scalable, and flexible manufacturing process is crucial to ensure these novel therapies reach patients.
This symposium showcases how the combination of Pall Life Sciences and Cytiva helps bring advanced therapies to patients faster and more efficiently by supplying complete solutions to support any process.
This session includes a customer case study (AGC Biologics Italy) on an efficient and scalable production process for lentiviral vectors, which can be further used for CAR-T manufacturing.
The second part is a roundtable with industry leaders from Anocca AB, TC BioPharm, Excellos, Fraunhofer IZI and University Hospital Basel on overcoming challenges and opportunities to advance new cell therapies.
Stephan Fricke PhD
Head of Department Cell- and Gene Therapy Development
Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Speakers
Head of Department Cell- and Gene Therapy Development
Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Speakers
